Updating perspectives on the initiation of Bacillus anthracis growth and dissemination through its host

Infection and Immunity

Volumn 80, Issue 5, 2012, Pages 1626-1633

  Weiner, Zachary P ^a   Glomski, Ian J ^a  

^a UNIVERSITY OF VIRGINIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EXOTOXIN; VIRULENCE FACTOR;

ANTHRAX; ARTICLE; BACILLUS ANTHRACIS; BACTERIAL GROWTH; BACTERIAL SPORE; BACTERIAL TRANSMISSION; CELL FUNCTION; EXPERIMENTAL HOST; HOST CELL; HOST PATHOGEN INTERACTION; HUMAN; INNATE IMMUNITY; LUNG; LUNG ALVEOLUS EPITHELIUM; LUNG ALVEOLUS MACROPHAGE; LYMPHATIC SYSTEM; LYMPHOID TISSUE; NONHUMAN; PATHOGENESIS; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL;

ANIMALS; ANTHRAX; BACILLUS ANTHRACIS; LUNG; MACROPHAGES, ALVEOLAR; SPORES, BACTERIAL;

EID: 84861133677     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.06061-11     Document Type: Article

References (78)

1. Abramova FA, Grinberg LM, Yampolskaya OV, Walker DH. 1993. Pathology of inhalational anthrax in 42 cases from the Sverdlovsk outbreak of 1979. Proc. Natl. Acad. Sci. U. S. A. 90:2291-2294.
2. Agrawal A, et al. 2003. Impairment of dendritic cells and adaptive immunity by anthrax lethal toxin. Nature 424:329-334.
3. Albrink WS, Goodlow RJ. 1959. Experimental inhalation anthrax in the chimpanzee. Am. J. Pathol. 35:1055-1065.
4. Barth H, Aktories K, Popoff MR, Stiles BG. 2004. Binary bacterial toxins: biochemistry, biology, and applications of common Clostridium and Bacillus proteins. Microbiol. Mol. Biol. Rev. 68:373-402.
5. Beatty ME, Ashford DA, Griffin PM, Tauxe RV, Sobel J. 2003. Gastrointestinal anthrax: review of the literature. Arch. Intern. Med. 163:2527-2531.
6. Bischof TS, Hahn BL, Sohnle PG. 2007. Experimental cutaneous Bacillus anthracis infections in hairless HRS/J. mice. Int. J. Exp. Pathol. 88:75-84.
7. Brittingham KC, et al. 2005. Dendritic cells endocytose Bacillus anthracis spores: implications for anthrax pathogenesis. J. Immunol. 174:5545-5552.
8. Brookmeyer R, Blades N. 2002. Prevention of inhalational anthrax in the U.S. outbreak. Science 295:1861.
9. Candela T, Fouet A. 2005. Bacillus anthracis CapD, belonging to the gamma-glutamyltranspeptidase family, is required for the covalent anchoring of capsule to peptidoglycan. Mol. Microbiol. 57:717-726.
10. Carrera M, Zandomeni RO, Fitzgibbon J, Sagripanti JL. 2007. Difference between the spore sizes of Bacillus anthracis and other Bacillus species. J. Appl. Microbiol. 102:303-312.
11. Chung MC, et al. 2006. Secreted neutral metalloproteases of Bacillus anthracis as candidate pathogenic factors. J. Biol. Chem. 281:31408-31418.
12. Cleret A, et al. 2007. Lung dendritic cells rapidly mediate anthrax spore entry through the pulmonary route. J. Immunol. 178:7994-8001.
13. Cossart P, Sansonetti PJ. 2004. Bacterial invasion: the paradigms of enteroinvasive pathogens. Science 304:242-248.
14. Cote CK, Bozue J, Twenhafel N, Welkos SL. 2009. Effects of altering the germination potential of Bacillus anthracis spores by exogenous means in a mouse model. J. Med. Microbiol. 58:816-825.
15. Cote CK, Rea KM, Norris SL, van Rooijen N, Welkos SL. 2004. The use of a model of in vivo macrophage depletion to study the role of macrophages during infection with Bacillus anthracis spores. Microb. Pathog. 37:169-175.
16. Cote CK, Van Rooijen N, Welkos SL. 2006. Roles of macrophages and neutrophils in the early host response to Bacillus anthracis spores in a mouse model of infection. Infect. Immun. 74:469-480.
17. Crawford MA, Aylott CV, Bourdeau RW, Bokoch GM. 2006. Bacillus anthracis toxins inhibit human neutrophil NADPH oxidase activity. J. Immunol. 176:7557-7565.
18. Dixon TC, Fadl AA, Koehler TM, Swanson JA, Hanna PC. 2000. Early Bacillus anthracis-macrophage interactions: intracellular survival and escape. Cell. Microbiol. 2:453-463.
19. Druett HA, Henderson DW, Packman L, Peacock S. 1953. Studies on respiratory infection. I. The influence of particle size on respiratory infection with anthrax spores. J. Hyg. (Lond.) 51:359-371.
20. Duesbery NS, et al. 1998. Proteolytic inactivation of MAP-kinase-kinase by anthrax lethal factor. Science 280:734-737.
21. Dumetz F, et al. 2011. Noninvasive imaging technologies reveal edema toxin as a key virulence factor in anthrax. Am. J. Pathol. 178:2523-2535.
22. Firoved AM, et al. 2005. Bacillus anthracis edema toxin causes extensive tissue lesions and rapid lethality in mice. Am. J. Pathol. 167:1309-1320.
23. Fraenkel E. 1924. Uber Inhalationsmilzbrand. Virchows Arch. Pathol. Anat. Physiol. 254:363-378.
24. Friedlander AM. 1997. Anthrax, p 467-478. In Zajtchuk R (ed), Medical aspects of chemical and biological warfare. Office of the Surgeon General, Borden Institute, Walter Reed Army Medical Center, Washington, DC.
25. Friedlander AM, et al. 1993. Postexposure prophylaxis against experimental inhalation anthrax. J. Infect. Dis. 167:1239-1243.
26. Fritz DL, et al. 1995. Pathology of experimental inhalation anthrax in the rhesus monkey. Lab. Invest. 73:691-702.
27. Gerhardt P. 1967. Cytology of Bacillus anthracis. Fed. Proc. 26:1504-1517.
28. Glomski IJ, et al. 2008. Inhaled non-capsulated Bacillus anthracis in A/J mice: nasopharynx and alveolar space as dual portals of entry, delayed dissemination, and specific organ targeting. Microbes Infect. 10:1398-1404.
29. Glomski IJ, et al. 2007. Murine splenocytes produce inflammatory cytokines in a MyD88-dependent response to Bacillus anthracis spores. Cell. Microbiol. 9:502-513.
30. Glomski IJ, Piris-Gimenez A, Huerre M, Mock M, Goossens PL. 2007. Primary involvement of pharynx and Peyer's patch in inhalational and intestinal anthrax. PLoS Pathog. 3:e76.
31. Goossens PL. 2009. Animal models of human anthrax: the quest for the Holy Grail. Mol. Aspects Med. 30:467-480.
32. Greenfield WS. 1882. Supplementary report on woolsorters disease in the Bradford district. Local Government Board, London, United Kingdom.
33. Grinberg LM, Abramova FA, Yampolskaya OV, Walker DH, Smith JH. 2001. Quantitative pathology of inhalational anthrax I: quantitative microscopic findings. Mod. Pathol. 14:482-495.
34. Guidi-Rontani C. 2002. The alveolar macrophage: the Trojan horse of Bacillus anthracis. Trends Microbiol. 10:405-409.
35. Guidi-Rontani C, Levy M, Ohayon H, Mock M. 2001. Fate of germinated Bacillus anthracis spores in primary murine macrophages. Mol. Microbiol. 42:931-938.
36. Guidi-Rontani C, Weber-Levy M, Labruyere E, Mock M. 1999. Germination of Bacillus anthracis spores within alveolar macrophages. Mol. Microbiol. 31:9-17.
37. Hanna PC, Kruskal BA, Ezekowitz RA, Bloom BR, Collier RJ. 1994. Role of macrophage oxidative burst in the action of anthrax lethal toxin. Mol. Med. 1:7-18.
38. Harper GJ, Morton JD. 1953. The respiratory retention of bacterial aerosols: experiments with radioactive spores. J. Hyg. (Lond.) 51:372-385.
39. Henderson DW, Peacock S, Belton FC. 1956. Observations on the prophylaxis of experimental pulmonary anthrax in the monkey. J. Hyg. (Lond.) 54:28-36.
40. Hu H, Sa Q, Koehler TM, Aronson AI, Zhou D. 2006. Inactivation of Bacillus anthracis spores in murine primary macrophages. Cell. Microbiol. 8:1634-1642.
41. Inglesby TV, et al. 2002. Anthrax as a biological weapon, 2002: updated recommendations for management. JAMA 287:2236-2252.
42. Ivanova N, et al. 2003. Genome sequence of Bacillus cereus and comparative analysis with Bacillus anthracis. Nature 423:87-91.
43. Kang TJ, et al. 2005. Murine macrophages kill the vegetative form of Bacillus anthracis. Infect. Immun. 73:7495-7501.
44. Kintzer AF, et al. 2009. The protective antigen component of anthrax toxin forms functional octameric complexes. J. Mol. Biol. 392:614-629.
45. Koch R. 1878. Die Aetiologie der Milzbrand-Krankheit bergundet auf die Entwicklungsgeschichte des Bacillus anthracis. Beitr. Biol. Pflazen 2:277-311.
46. Leppla SH. 1982. Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells. Proc. Natl. Acad. Sci. U. S. A. 79:3162-3166.
47. Lincoln RE, et al. 1965. Role of the lymphatics in the pathogenesis of anthrax. J. Infect. Dis. 115:481-494.
48. Liu S, et al. 2010. Anthrax toxin targeting of myeloid cells through the CMG2 receptor is essential for establishment of Bacillus anthracis infections in mice. Cell Host Microbe 8:455-462.
49. Loving CL, et al. 2009. Role of anthrax toxins in dissemination, disease progression, and induction of protective adaptive immunity in the mouse aerosol challenge model. Infect. Immun. 77:255-265.
50. Makino S, Uchida I, Terakado N, Sasakawa C, Yoshikawa M. 1989. Molecular characterization and protein analysis of the cap region, which is essential for encapsulation in Bacillus anthracis. J. Bacteriol. 171:722-730.
51. Makino S, Watarai M, Cheun HI, Shirahata T, Uchida I. 2002. Effect of the lower molecular capsule released from the cell surface of Bacillus anthracis on the pathogenesis of anthrax. J. Infect. Dis. 186:227-233.
52. Maldonado-Arocho FJ, Bradley KA. 2009. Anthrax edema toxin induces maturation of dendritic cells and enhances chemotaxis towards macrophage inflammatory protein 3beta. Infect. Immun. 77:2036-2042.
53. Manchee RJ, Broster MG, Stagg AJ, Hibbs SE. 1994. Formaldehyde solution effectively inactivates spores of Bacillus anthracis on the Scottish island of Gruinard. Appl. Environ. Microbiol. 60:4167-4171.
54. Mayer-Scholl A, et al. 2005. Human neutrophils kill Bacillus anthracis. PLoS Pathog. 1:e23.
55. Mayer TA, et al. 2003. Inhalational anthrax due to bioterrorism: would current Centers for Disease Control and Prevention guidelines have identified the 11 patients with inhalational anthrax from October through November 2001? Clin. Infect. Dis. 36:1275-1283.
56. Moayeri M, et al. 2010. Inflammasome sensor Nlrp1b-dependent resistance to anthrax is mediated by caspase-1, IL-1 signaling and neutrophil recruitment. PLoS Pathog. 6:e1001222.
57. Moayeri M, Haines D, Young HA, Leppla SH. 2003. Bacillus anthracis lethal toxin induces TNF-alpha-independent hypoxia-mediated toxicity in mice. J. Clin. Invest. 112:670-682.
58. Mock M, Fouet A. 2001. Anthrax. Annu. Rev. Microbiol. 55:647-671.
59. Popov SG, et al. 2005. Effective antiprotease-antibiotic treatment of experimental anthrax. BMC Infect. Dis. 5:25.
60. Ramsay CN, et al. An outbreak of infection with Bacillus anthracis in injecting drug users in Scotland. Euro Surveill. 15(2):pii=19465.
61. Richter S, et al. 2009. Capsule anchoring in Bacillus anthracis occurs by a transpeptidation reaction that is inhibited by capsidin. Mol. Microbiol. 71:404-420.
62. Ross JM. 1957. The pathogenesis of anthrax following the administration of spores by the respiratory route J. Pathol. Bacteriol. 73:9.
63. Russell BH, et al. 2008. In vivo demonstration and quantification of intracellular Bacillus anthracis in lung epithelial cells. Infect. Immun. 76: 3975-3983.
64. Russell BH, Vasan R, Keene DR, Xu Y. 2007. Bacillus anthracis internalization by human fibroblasts and epithelial cells. Cell. Microbiol. 9:1262-1274.
65. Ruthel G, Ribot WJ, Bavari S, Hoover TA. 2004. Time-lapse confocal imaging of development of Bacillus anthracis in macrophages. J. Infect. Dis. 189:1313-1316.
66. Sanz P, et al. 2008. Detection of Bacillus anthracis spore germination in vivo by bioluminescence imaging. Infect. Immun. 76:1036-1047.
67. Schneerson R, et al. 2003. Poly(gamma-D-glutamic acid) protein conjugates induce IgG antibodies in mice to the capsule of Bacillus anthracis: a potential addition to the anthrax vaccine. Proc. Natl. Acad. Sci. U. S. A. 100:8945-8950.
68. Tacke F, Randolph GJ. 2006. Migratory fate and differentiation of blood monocyte subsets. Immunobiology 211:609-618.
69. Tessier J, et al. 2007. Contributions of histamine, prostanoids, and neurokinins to edema elicited by edema toxin from Bacillus anthracis. Infect. Immun. 75:1895-1903.
70. Tournier JN, et al. 2005. Anthrax edema toxin cooperates with lethal toxin to impair cytokine secretion during infection of dendritic cells. J. Immunol. 174:4934-4941.
71. Turnbull PC. 1999. Definitive identification of Bacillus anthracis-a review. J. Appl. Microbiol. 87:237-240.
72. van Sorge NM, et al. 2008. Anthrax toxins inhibit neutrophil signaling pathways in brain endothelium and contribute to the pathogenesis of meningitis. PLoS One 3:e2964.
73. Walsh JJ, et al. 2007. A case of naturally acquired inhalation anthrax: clinical care and analyses of anti-protective antigen immunoglobulin G and lethal factor. Clin. Infect. Dis. 44:968-971.
74. Warfel JM, Steele AD, D'Agnillo F. 2005. Anthrax lethal toxin induces endothelial barrier dysfunction. Am. J. Pathol. 166:1871-1881.
75. Watts CJ, Hahn BL, Sohnle PG. 2009. Resistance of athymic nude mice to experimental cutaneous Bacillus anthracis infection. J. Infect. Dis. 199:673-679.
76. WHO. 2008. Anthrax in humans and animals. World Health Organization, Geneva, Switzerland.
77. Wu W, et al. 2009. Resistance of human alveolar macrophages to Bacillus anthracis lethal toxin. J. Immunol. 183:5799-5806.
78. Young GA, Jr, Zelle MR, Lincoln RE. 1946. Respiratory pathogenicity of Bacillus anthracis spores; methods of study and observations on pathogenesis. J. Infect. Dis. 79:233-246.